Barbara L. Leighton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Barbara L. Leighton has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Ellen M. Lockhart
3 shared publicationsAmanda J. Zatta
2 shared publicationsLouise E. Phillips
2 shared publicationsMichael H. Wall
2 shared publications- Daniel Nissman
University of North Carolina School of Medicine
1 shared publication Kathleen W. Nissman
Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA
1 shared publication
Latest Publications
- Open Access
- 14 December 2012
- Published by Springer Nature in Israel Journal of Health Policy Research
- Vol. 1 (1) , 49
A first step in determining appropriate amounts of obstetric anesthesia work
Ginosar, et al. describe a new performance indicator, the Obstetric Anesthesia Activity Index, to represent the current amount of obstetric anesthesia work done daily at each of 25 Israeli hospitals. The authors claim, correctly, that this index is a closer reflection of the anesthetic workload than simply looking at the number of deliveries at each hospital. However, the Obstetric Anesthesia Activity Index could easily be refined to reflect more closely the actual obstetric anesthesia workload by using the average cesarean delivery time for each hospital rather than one value for all hospitals. Although the authors state that they developed the Obstetric Anesthesia Activity Index out of concern for inadequate obstetric anesthesia manpower in Israel, they have not compared the Obstetric Anesthesia Activity Index with the size of the patient population or any measure of patient satisfaction or patient safety. In its current form, the Obstetric Anesthesia Activity Index describes the current work situation but does not evaluate the extent of the unmet need for additional anesthesia providers. Despite these shortcomings, the Obstetric Anesthesia Activity Index is an important first step in developing a tool to assess unmet obstetric anesthesia needs.
- 14 December 2012
- Published by Springer Nature in Israel Journal of Health Policy Research
- Vol. 1 (1) , 49
Open AccessA first step in determining appropriate amounts of obstetric anesthesia work
Ginosar, et al. describe a new performance indicator, the Obstetric Anesthesia Activity Index, to represent the current amount of obstetric anesthesia work done daily at each of 25 Israeli hospitals. The authors claim, correctly, that this index is a closer reflection of the anesthetic workload than simply looking at the number of deliveries at each hospital. However, the Obstetric Anesthesia Activity Index could easily be refined to reflect more closely the actual obstetric anesthesia workload by using the average cesarean delivery time for each hospital rather than one value for all hospitals. Although the authors state that they developed the Obstetric Anesthesia Activity Index out of concern for inadequate obstetric anesthesia manpower in Israel, they have not compared the Obstetric Anesthesia Activity Index with the size of the patient population or any measure of patient satisfaction or patient safety. In its current form, the Obstetric Anesthesia Activity Index describes the current work situation but does not evaluate the extent of the unmet need for additional anesthesia providers. Despite these shortcomings, the Obstetric Anesthesia Activity Index is an important first step in developing a tool to assess unmet obstetric anesthesia needs.
- Open Access
- 1 August 2012
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 117 (2) , 423-424
In Reply
The United Kingdom Obstetric Surveillance System (UKOSS) report was published after we had finished collecting data and shortly before we submitted our manuscript to ANESTHESIOLOGY.1,2 We apologize for the oversight; we certainly would have contacted Knight had we been aware of UKOSS at that time. However, it is unclear how many of the cases in the UKOSS database would have qualified for our review. We employed the traditional definition of amniotic fluid embolism (AFE) used by the United Kingdom AFE register and the United States AFE registry.3,4 Patients had to have at least one major cardiac and one major pulmonary symptom (or cardiopulmonary arrest) plus consumptive coagulopathy to be diagnosed with AFE. In contrast, UKOSS used a much broader definition of AFE; for example, 38% of the UKOSS AFE patients did not have a coagulopathy.1 This is not a trivial distinction, for patients who do not meet the traditional definition of AFE seem to have better outcomes after receiving recombinant factor VIIa (rVIIa) than patients who do meet the definition, as seen in these case reports.5,6 We believe that the broader definition of AFE used by UKOSS permitted the enrollment of patients with similar but different diseases.
- 1 August 2012
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 117 (2) , 423-424
Open AccessIn Reply
The United Kingdom Obstetric Surveillance System (UKOSS) report was published after we had finished collecting data and shortly before we submitted our manuscript to ANESTHESIOLOGY.1,2 We apologize for the oversight; we certainly would have contacted Knight had we been aware of UKOSS at that time. However, it is unclear how many of the cases in the UKOSS database would have qualified for our review. We employed the traditional definition of amniotic fluid embolism (AFE) used by the United Kingdom AFE register and the United States AFE registry.3,4 Patients had to have at least one major cardiac and one major pulmonary symptom (or cardiopulmonary arrest) plus consumptive coagulopathy to be diagnosed with AFE. In contrast, UKOSS used a much broader definition of AFE; for example, 38% of the UKOSS AFE patients did not have a coagulopathy.1 This is not a trivial distinction, for patients who do not meet the traditional definition of AFE seem to have better outcomes after receiving recombinant factor VIIa (rVIIa) than patients who do meet the definition, as seen in these case reports.5,6 We believe that the broader definition of AFE used by UKOSS permitted the enrollment of patients with similar but different diseases.
- 1 December 2011
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 115 (6) , 1201-1208
Use of Recombinant Factor VIIa in Patients with Amniotic Fluid Embolism
Background: Patients with amniotic fluid embolism (AFE) (major cardiac and pulmonary symptoms plus consumptive coagulopathy) have high circulating tissue factor concentrations. Recombinant factor VIIa (rVIIa) has been used to treat hemorrhage in AFE patients even though rVIIa can combine with circulating tissue factor and form intravascular clots. A systematic review was done of case reports from 2003 to 2009 of AFE patients with massive hemorrhage who were and were not treated with rVIIa to assess the thrombotic complication risk. Methods: MEDLINE was searched for case reports of AFE patients receiving rVIIa (rVIIa cases) and of AFE patients who received surgery to control bleeding but no rVIIa (cohorts who did not receive rVIIa). Additional AFE case reports were obtained from the Food and Drug Administration, the Australian and New Zealand Haemostasis Registry, and scientific meeting abstracts. The risk of a negative outcome (permanent disability or death) in rVIIa cases versus cohorts who did not receive rVIIa was calculated using risk ratio and 95% confidence interval. Results: Sixteen rVIIa cases and 28 cohorts were identified who did not receive rVIIa. All patients had surgery to control bleeding. Death, permanent disability, and full recovery occurred in 8, 6, and 2 rVIIa cases and 7, 4, and 17 cohorts who did not receive rVIIa (risk ratio 2.2, 95% CI 1.4-3.7 for death or permanent disability vs. full recovery). Conclusion: Recombinant factor VIIa cases had significantly worse outcomes than cohorts who did not receive rVIIa. It is recommended that rVIIa be used in AFE patients only when the hemorrhage cannot be stopped by massive blood component replacement.
- 1 December 2011
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 115 (6) , 1201-1208
Use of Recombinant Factor VIIa in Patients with Amniotic Fluid Embolism
Background: Patients with amniotic fluid embolism (AFE) (major cardiac and pulmonary symptoms plus consumptive coagulopathy) have high circulating tissue factor concentrations. Recombinant factor VIIa (rVIIa) has been used to treat hemorrhage in AFE patients even though rVIIa can combine with circulating tissue factor and form intravascular clots. A systematic review was done of case reports from 2003 to 2009 of AFE patients with massive hemorrhage who were and were not treated with rVIIa to assess the thrombotic complication risk. Methods: MEDLINE was searched for case reports of AFE patients receiving rVIIa (rVIIa cases) and of AFE patients who received surgery to control bleeding but no rVIIa (cohorts who did not receive rVIIa). Additional AFE case reports were obtained from the Food and Drug Administration, the Australian and New Zealand Haemostasis Registry, and scientific meeting abstracts. The risk of a negative outcome (permanent disability or death) in rVIIa cases versus cohorts who did not receive rVIIa was calculated using risk ratio and 95% confidence interval. Results: Sixteen rVIIa cases and 28 cohorts were identified who did not receive rVIIa. All patients had surgery to control bleeding. Death, permanent disability, and full recovery occurred in 8, 6, and 2 rVIIa cases and 7, 4, and 17 cohorts who did not receive rVIIa (risk ratio 2.2, 95% CI 1.4-3.7 for death or permanent disability vs. full recovery). Conclusion: Recombinant factor VIIa cases had significantly worse outcomes than cohorts who did not receive rVIIa. It is recommended that rVIIa be used in AFE patients only when the hemorrhage cannot be stopped by massive blood component replacement.
- 1 December 2011
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 115 (6) , 1301
Necrotizing Fasciitis after Cesarean Delivery
THIS 27-yr-old patient (preoperative body mass index, 32 kg/m2) presented 12 days after a repeat cesarean delivery. The patient complained of pain, swelling, and a 6 × 4-cm complex mass of blood-filled bullae on her abdominal panniculus, 7 cm from her well-healed incision. She was afebrile and not diabetic. Her hemoglobin concentration was 8.3 g/dl; leukocyte count, 23,200/ml; and creatinine concentration, 3.9 mg/dl. Bleeding, not infection, was suspected; necrotizing fasciitis was not diagnosed until the computed tomographic scan was examined (fig.). Surgical debridement required removal of 75% of the panniculus. The patient went to intensive care intubated, on a phenylephrine infusion, with her open wound packed. She was discharged home with negative-pressure wound therapy. The wound healed completely, and the patient's renal function normalized.
- 1 December 2011
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 115 (6) , 1301
Necrotizing Fasciitis after Cesarean Delivery
THIS 27-yr-old patient (preoperative body mass index, 32 kg/m2) presented 12 days after a repeat cesarean delivery. The patient complained of pain, swelling, and a 6 × 4-cm complex mass of blood-filled bullae on her abdominal panniculus, 7 cm from her well-healed incision. She was afebrile and not diabetic. Her hemoglobin concentration was 8.3 g/dl; leukocyte count, 23,200/ml; and creatinine concentration, 3.9 mg/dl. Bleeding, not infection, was suspected; necrotizing fasciitis was not diagnosed until the computed tomographic scan was examined (fig.). Surgical debridement required removal of 75% of the panniculus. The patient went to intensive care intubated, on a phenylephrine infusion, with her open wound packed. She was discharged home with negative-pressure wound therapy. The wound healed completely, and the patient's renal function normalized.